Corrigendum to: Increased risk of gastrointestinal acute GVHD following the addition of melphalan to busulfan/cyclophosphamide conditioning (Pediatric Transplantation, (2013), 17, 3, (285-293), 10.1111/petr.12061);Increased risk of gastrointestinal acute GVHD following the addition of melphalan to busulfan/cyclophosphamide conditioning

Pediatric Transplantation

Volumn 17, Issue 3, 2013, Pages 285-293

  Martensson, T ^a,b   Priftakis, P ^a,b   Casswall, T ^a,b   Ringden O ^a   Mattsson, J ^a   Hassan, M ^a,b   Gustafsson, B ^a,b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

busulfan; graft versus host disease; gut toxicity; juvenile myelomonocytic leukemia; melphalan; myelodysplastic syndrome

Indexed keywords

BILIRUBIN; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; MELPHALAN; METHOTREXATE; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADENOVIRUS; ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; CANDIDA; CAUSE OF DEATH; CHILD; CHRONOPHARMACOLOGY; CLINICAL ARTICLE; CLOSTRIDIUM DIFFICILE; CYTOMEGALOVIRUS; DIARRHEA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG TREATMENT FAILURE; FEMALE; GASTROINTESTINAL DISEASE; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HEMORRHAGIC CYSTITIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFANT; INFECTION; JUVENILE MYELOMONOCYTIC LEUKEMIA; LIVER DISEASE; LYMPHOPROLIFERATIVE DISEASE; MALE; MYELODYSPLASTIC SYNDROME; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRESCHOOL CHILD; PROGNOSIS; RECURRENCE RISK; RETRANSPLANTATION; RETROSPECTIVE STUDY; RISK ASSESSMENT; SCHOOL CHILD; SURVIVAL RATE; THROMBOCYTOPENIA;

EID: 84876704034     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/petr.14079     Document Type: Erratum

References (39)

1. Hasle H,. Myelodysplastic and myeloproliferative disorders in children. Curr Opin Pediatr 2007: 19: 1-8.
2. Fry TJ,. Expanding options to improve outcomes following hematopoietic stem cell transplantation. Pediatr Blood Cancer 2010: 55: 1043-1044.
3. Niemeyer CM, Kratz CP,. Paediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia: Molecular classification and treatment options. Br J Haematol 2008: 140: 610-624.
4. Chan RJ, Cooper T, Kratz CP, Weiss B, Loh ML,. Juvenile myelomonocytic leukemia: A report from the 2nd International JMML Symposium. Leuk Res 2009: 33: 355-362.
5. Eapen M, Horowitz MM, Klein JP, et al. Higher mortality after allogeneic peripheral-blood transplantation compared with bone marrow in children and adolescents: The Histocompatibility and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant Registry. J Clin Oncol 2004: 22: 4872-4880.
6. Giebel S, Giorgiani G, Martinetti M, et al. Low incidence of severe acute graft-versus-host disease in children given haematopoietic stem cell transplantation from unrelated donors prospectively matched for HLA class I and II alleles with high-resolution molecular typing. Bone Marrow Transplant 2003: 31: 987-993.
7. Jacobsohn DA, Hewlett B, Ranalli M, Seshadri R, Duerst R, Kletzel M,. Outcomes of unrelated cord blood transplants and allogeneic-related hematopoietic stem cell transplants in children with high-risk acute lymphocytic leukemia. Bone Marrow Transplant 2004: 34: 901-907.
8. Wall DA, Carter SL, Kernan NA, et al. Busulfan/melphalan/antithymocyte globulin followed by unrelated donor cord blood transplantation for treatment of infant leukemia and leukemia in young children: The Cord Blood Transplantation study (COBLT) experience. Biol Blood Marrow Transplant 2005: 11: 637-646.
9. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995: 15: 825-828.
10. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974: 18: 295-304.
11. Strahm B, Nollke P, Zecca M, et al. Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome in children: results of the EWOG-MDS 98 study. Leukemia 2011: 25: 455-462.
12. Locatelli F, Nollke P, Zecca M, et al. Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): Results of the EWOG-MDS/EBMT trial. Blood 2005: 105: 410-419.
13. Zwaveling J, Bredius RG, Cremers SC, et al. Intravenous busulfan in children prior to stem cell transplantation: Study of pharmacokinetics in association with early clinical outcome and toxicity. Bone Marrow Transplant 2005: 35: 17-23.
14. Cheuk DK, Wang P, Lee TL, et al. Risk factors and mortality predictors of hepatic veno-occlusive disease after pediatric hematopoietic stem cell transplantation. Bone Marrow Transplant 2007: 40: 935-944.
15. Tsuboi K, Kishi K, Ohmachi K, et al. Multivariate analysis of risk factors for hemorrhagic cystitis after hematopoietic stem cell transplantation. Bone Marrow Transplant 2003: 32: 903-907.
16. Ferrara JL, Deeg HJ,. Graft-versus-host disease. N Engl J Med 1991: 324: 667-674.
17. Goldberg J, Jacobsohn DA, Zahurak ML, Vogelsang GB,. Gastrointestinal toxicity from the preparative regimen is associated with an increased risk of graft-versus-host disease. Biol Blood Marrow Transplant 2005: 11: 101-107.
18. Liu D, Yan C, Xu L, et al. Diarrhea during the conditioning regimen is correlated with the occurrence of severe acute graft-versus-host disease through systemic release of inflammatory cytokines. Biol Blood Marrow Transplant 2010: 16: 1567-1575.
19. Johansson JE, Ekman T,. Gut toxicity during hemopoietic stem cell transplantation may predict acute graft-versus-host disease severity in patients. Dig Dis Sci 2007: 52: 2340-2345.
20. Hagen LE, Schechter T, Luk Y, Brodovitch A, Gassas A, Doyle JJ,. High alpha-1 antitrypsin clearance predicts severity of gut graft-versus-host disease (GVHD) in children. Pediatr Transplant 2011: 15: 659-663.
21. Hassan M, Ljungman P, Ringden O, et al. The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: Time interval influence on therapeutic efficacy and therapy-related toxicity. Bone Marrow Transplant 2000: 25: 915-924.
22. Jones RJ, Lee KS, Beschorner WE, et al. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation 1987: 44: 778-783.
23. Hassan M, Ljungman P, Bolme P, et al. Busulfan bioavailability. Blood 1994: 84: 2144-2150.
24. Hasle H, Baumann I, Bergstrasser E, et al. The International Prognostic Scoring System (IPSS) for childhood myelodysplastic syndrome (MDS) and juvenile myelomonocytic leukemia (JMML). Leukemia 2004: 18: 2008-2014.
25. Pescovitz MD, Navarro MT,. Immunosuppressive therapy and post-transplantation diarrhea. Clin Transplant 2001: 15 (Suppl 4): 23-28.
26. Holler E, Rogler G, Herfarth H, et al. Both donor and recipient NOD2/CARD15 mutations associate with transplant-related mortality and GvHD following allogeneic stem cell transplantation. Blood 2004: 104: 889-894.
27. Gorczynska E, Turkiewicz D, Rybka K, et al. Incidence, clinical outcome, and management of virus-induced hemorrhagic cystitis in children and adolescents after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2005: 11: 797-804.
28. Dalianis T, Ljungman P,. Full myeloablative conditioning and an unrelated HLA mismatched donor increase the risk for BK virus-positive hemorrhagic cystitis in allogeneic hematopoetic stem cell transplanted patients. Anticancer Res 2011: 31: 939-944.
29. Bartelink IH, Bredius RG, Belitser SV, et al. Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematologic stem cell transplantation. Biol Blood Marrow Transplant: journal of the American Society for Blood and Marrow Transplantation 2009: 15: 231-241.
30. Meresse V, Hartmann O, Vassal G, et al. Risk factors for hepatic veno-occlusive disease after high-dose busulfan-containing regimens followed by autologous bone marrow transplantation: A study in 136 children. Bone Marrow Transplant 1992: 10: 135-141.
31. Bouligand J, Boland I, Valteau-Couanet D, et al. In children and adolescents, the pharmacodynamics of high-dose busulfan is dependent on the second alkylating agent used in the combined regimen (melphalan or thiotepa). Bone Marrow Transplant 2003: 32: 979-986.
32. Tran HT, Madden T, Petropoulos D, et al. Individualizing high-dose oral busulfan: Prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies. Bone Marrow Transplant 2000: 26: 463-470.
33. Hassan Z, Remberger M, Svenberg P, et al. Hemorrhagic cystitis: A retrospective single-center survey. Clin Transplant 2007: 21: 659-667.
34. Vassal G, Challine D, Koscielny S, et al. Chronopharmacology of high-dose busulfan in children. Cancer Res 1993: 53: 1534-1537.
35. Hassan M, Oberg G, Bekassy AN, et al. Pharmacokinetics of high-dose busulphan in relation to age and chronopharmacology. Cancer Chemother Pharmacol 1991: 28: 130-134.
36. Baraldo M,. The influence of circadian rhythms on the kinetics of drugs in humans. Expert Opin Drug Metab Toxicol 2008: 4: 175-192.
37. Zhang YK, Yeager RL, Klaassen CD,. Circadian expression profiles of drug-processing genes and transcription factors in mouse liver. Drug Metab Dispos 2009: 37: 106-115.
38. Gibbs JP, Czerwinski M, Slattery JT,. Busulfan-glutathione conjugation catalyzed by human liver cytosolic glutathione S-transferases. Cancer Res 1996: 56: 3678-3681.
39. Awasthi S, Bajpai KK, Piper JT, et al. Interactions of melphalan with glutathione and the role of glutathione S-transferase. Drug Metab Dispos 1996: 24: 371-374.